Product Description
Lundbeck is developing LU-AF82422 as a treatment for multiple system atrophy. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05104476)
Mechanisms of Action: aSYN Binder
Novel Mechanism: Yes
Modality: Antibody
Route of Administration: Intravenous
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Lundbeck
Company Location: DENMARK G7 00000
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, China, France, Germany, Italy, Japan, Korea, Poland, Spain, United Kingdom, United States
Active Clinical Trial Count: 7
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Multiple System Atrophy|Shy-Drager Syndrome
Phase 2: Pure Autonomic Failure
Phase 1: Healthy Volunteers
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05104476 |
AMULET | P2 |
Active, not recruiting |
Pure Autonomic Failure|Multiple System Atrophy |
2023-11-16 |
12% |
2025-08-27 |
Primary Endpoints|Study Completion Date|Treatments |
NCT06706622 |
MASCOT | P3 |
Recruiting |
Multiple System Atrophy|Shy-Drager Syndrome |
2028-02-17 |
38% |
2024-12-05 |
Primary Endpoints|Treatments|Trial Status |
CTR20240449 |
CTR20240449 | P1 |
Completed |
Multiple System Atrophy |
2024-09-03 |
2025-04-29 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
jRCT2021240061 |
jRCT2021240061 | P3 |
Recruiting |
Multiple System Atrophy |
2029-10-25 |
|||
2024-517169-18-00 |
20432A | P3 |
Not yet recruiting |
Multiple System Atrophy |
2029-10-31 |
38% |
2025-05-02 |
Treatments |
jRCT2021210061 |
jRCT2021210061 | P2 |
Active, not recruiting |
Multiple System Atrophy |
2023-08-30 |
|||
NCT06258720 |
19728A | P1 |
Completed |
Healthy Volunteers |
2024-09-03 |
50% |
2024-11-13 |
Primary Endpoints |